Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.53 |
| ▸ | LIPC | P11150 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21669125 | 1.00 | LIPG (0.53) | LIPGLIPCUSP2ACACBFFAR4 | |
| SCHEMBL21638237 | 1.00 | LIPG (0.53) | LIPGLIPCUSP2ACACBFFAR4 | |
| SCHEMBL21669102 | 0.85 | LIPG (0.47) | LIPGLIPCACACB | |
| SCHEMBL23839397 | 0.85 | LIPG (0.47) | LIPGLIPCACACB | |
| SCHEMBL21669124 | 0.85 | LIPG (0.47) | LIPGLIPCACACB | |
| SCHEMBL4578782 | 0.84 | USP2 (0.60) | USP2ACACBFFAR4HRH1CCR3 | |
| SCHEMBL20046768 | 0.84 | USP2 (0.60) | USP2ACACBFFAR4HRH1CCR3 | |
| SCHEMBL8228558 | 0.84 | USP2 (0.60) | USP2ACACBFFAR4HRH1CCR3 | |
| SCHEMBL19297613 | 0.81 | LIPG (0.46) | LIPGLIPCACACBFFAR4KDM4E | |
| SCHEMBL24213939 | 0.81 | LIPG (0.60) | LIPGLIPCACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475775-B | 4-pyridone compound or salt thereof, pharmaceutical composition containing 4-pyridone compound, and agent | 富士胶片株式会社 | 2023-05-09 | — | — | CN | disclosed |
| US-11161830-B2 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | FUJIFILM CORPORATION (JP) | 2021-11-02 | — | — | US | disclosed |
| EP-3604301-B1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM CORP (JP) | 2021-09-22 | — | — | EP | disclosed |
| EP-3604301-A1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3604301-A1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110475775-A | 4- pyridinone compounds or its salt, pharmaceutical composition and agent comprising 4- pyridinone compounds | FUJIFILM CORP | 2019-11-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161830-B2 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | HAVCR2, HBS1L, PHKB | LIPG 4820/4885LIPC 3754/4885USP2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.